Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "Science"

2587 News Found

Sai Life Sciences completes Phase II of production block 11 at Bidar
News | August 29, 2025

Sai Life Sciences completes Phase II of production block 11 at Bidar

With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL


Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
News | August 17, 2025

Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr

The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase


Cohance Lifesciences reports 13% revenue growth in Q1 FY26
News | August 16, 2025

Cohance Lifesciences reports 13% revenue growth in Q1 FY26

During the quarter, construction began on a US$ 10 million bioconjugation cGMP suite at NJ Bio’s Princeton site


Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr
News | August 13, 2025

Zydus Lifesciences reports Q1 FY26 net profit at Rs. 1,466.8 Cr

The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY


Briefs: Nectar Lifesciences, Cipla and Marksans Pharma
News | August 12, 2025

Briefs: Nectar Lifesciences, Cipla and Marksans Pharma

Marksans Pharma gets USFDA nod for acid reflux drug


LAXAI Life Sciences appoints Sripathy Venkatraman as CEO
People | August 11, 2025

LAXAI Life Sciences appoints Sripathy Venkatraman as CEO

Dr. Venkatraman brings over 25 years of experience in small molecule and Biologics drug development, manufacturing, and advancing strategic growth initiatives


WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies
Biotech | August 08, 2025

WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies

The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines


Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
News | August 05, 2025

Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr

EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase